Associated Genetic Biomarkers
NCI Definition: A liposarcoma characterized by the presence of varying proportions of pleomorphic lipoblasts in a background that resembles undifferentiated pleomorphic sarcoma. It is the rarest liposarcoma variant and usually has an aggressive clinical course. 
Pleomorphic liposarcomas most frequently harbor alterations in TP53, RB1, ATRX, CYSLTR2, and SMARCA4 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Loss, and TP53fs are the most common alterations in pleomorphic liposarcoma .
There are 4 clinical trials for pleomorphic liposarcoma, of which 4 are open and 0 are completed or closed. Of the trials that contain pleomorphic liposarcoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).
PIK3CA and PTEN are the most frequent gene inclusion criteria for pleomorphic liposarcoma clinical trials .
Atezolizumab, bempegaldesleukin, and cobimetinib are the most common interventions in pleomorphic liposarcoma clinical trials.
Significant Genes in Pleomorphic Liposarcoma
PIK3CA is altered in 2.5% of pleomorphic liposarcoma patients .
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) .
PTEN is altered in 7.5% of pleomorphic liposarcoma patients .
PTEN is an inclusion eligibility criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.